FINWIRES · TerminalLIVE
FINWIRES

電信公司愛立信第一季獲利受重組成本和匯率不利因素影響

-- 根據週五發布的消息,愛立信(ERIC-B.ST、ERIC-A.ST、ERIBR.HE)第一季利潤同比下降,主要受重組費用和不利匯率波動的影響。 截至3月31日的三個月,這家電信集團的歸屬於股東的淨利為8.88億瑞典克朗,低於去年同期的41.5億瑞典克朗,也低於FactSet先前預測的35.7億瑞典克朗。每股盈餘從1.24瑞典克朗降至0.27瑞典克朗。 儘管報告的淨銷售額從550.3億瑞典克朗降至493.3億瑞典克朗,但該公司實現了6%的同比增長,反映出所有業務部門的強勁表現。 FactSet調查的分析師此前預期銷售額為509.2億瑞典克朗。 前三個月,愛立信調整後毛利率從48.5%降至48.1%,而報告毛利率為47.2%,略低於前期的48.2%。集團指出,雲端軟體和服務部門的利潤率有所提升,而網路業務的利潤率則略有下降。 「多年來,我們致力於建立一個具有韌性且多元化的供應鏈,這使我們能夠在地緣政治和宏觀經濟不確定性的背景下,持續為客戶提供服務。我們正面臨不斷上漲的投入成本,尤其是在半導體領域,部分原因是人工智能需求的增長。我們的目標是透過與客戶和供應商緊密合作,以及博子採取產品總裁和提高這些效率。他還補充道,公司專注於企業級和關鍵任務型業務,即使在無線接入網市場預期「趨於平穩」的情況下,也能增強其長期成長動能。 同時,愛立信計劃啟動一項價值150億瑞典克朗的股票回購計劃,旨在分配過剩流動性並履行其股權激勵計劃下的義務。該回購計畫將於2026年4月23日至2027年3月31日期間實施,B類股票的回購將由獨立公司執行。公司將回購規模限制在已發行股份總數的10%以內,並計劃註銷所有非激勵計畫所需的股份。 週五午後交易時段,愛立信股票在斯德哥爾摩上漲超過1%,在赫爾辛基小幅上漲。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA